NEW YORK, April 28, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ Capital Markets:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, today provided an operational update to the investment community, including financial results for the year ended December 31, 2016.
“In our first earnings report as a public company, we are pleased to provide the investment community with an update on our operations and insight into our clinical pipeline,” said Dr. Lan Huang, Ph.D., BeyondSpring CEO. “In March 2017, BeyondSpring successfully completed its initial public offering and concurrent private placement with Chinese and U.S. investors, significantly strengthening our balance sheet with an additional $48.17 million in total net proceeds.”
